Tanakan - instructions for use, dose, side effects, contraindications

lactose monohydrate - 82,50 mg, microcrystalline cellulose - 50,00 mg, corn starch - 37,00 mg, silicon dioxide colloid - 28,00 mg, talc - 11,25 mg, magnesium stearate - 1,25 mg.

Sheath:

Hypromellose (E 464) - 6.00 mg,Macheol 400 - 1.50 mg, Macrogol 6000 - 1.50 mg, titanium dioxide (E 171) - 1.00 mg, iron oxide red (E 172) - 0.70 mg.

Description:

Two-convex round tablets covered with a film shell of brick-red color.

On the break, the tablets have a light brown color and a specific odor.

Pharmacotherapeutic group:angioprotective agent of plant origin.

ATX: & nbsp

N.06.D.X.02 Ginkgo Biloba Leaf Extract

Pharmacodynamics:

Standardized and titrated preparation of plant origin; the effect of which is due to the influence on metabolic processes in cells, the rheological properties of blood, and the vasomotor reactions of blood vessels.

The drug improves the supply of the brain with oxygen and glucose.
Normalizes the tone of arteries and veins, improves microcirculation.
Helps improve blood flow, prevents the aggregation of red blood cells.
Has a retarding effect on the platelet activation factor.
Improved metabolic processes, has an antihypoxic effect on the tissue.
It interferes with the formation of free radicals and peroxide oxidation of cell membrane lipids.
Affects the release, reverse capture and catabolism of neurotransmitters (noradrenaline, acetylcholine, dopamine, serotonin) and their ability to bind to membrane receptors.

Pharmacokinetics:

Ginkgolides A and B and bilobalides have a bioavailability of 80% to 90% when taken orally. The maximum concentration is achieved in 1-2 hours; the half-life is from 4 hours (ginkgolid A and bilobalid) to 10 hours (Ginkgolide B). The main way of excretion is the kidneys.

Indications:

cognitive and sensorine deficiency of various genesis (with the exception of Alzheimer's disease and dementia of various etiologies);
intermittent claudication in chronic obliterating arteriopathies of the lower extremities (2nd degree according to Fontaine);
impaired vision of vascular genesis, a decrease in its severity;
hearing impairment, tinnitus, dizziness and coordination disorders of movements of predominantly vascular genesis;
disease and Reynaud's syndrome.

Contraindications:

Age to 18 years. Hypersensitivity to any of the components of the drug, erosive gastritis in the acute stage, peptic ulcer of the stomach and duodenal ulcer in the stage of exacerbation,acute disorders of cerebral circulation, acute myocardial infarction, congenital galactosemia, lactase deficiency, lactose intolerance, glucose-galactose malabsorption, reduced blood clotting.

Carefully:

Pregnancy and lactation:Due to the lack of clinical data on the use of the drug during pregnancy and breastfeeding, this drug is contraindicated.

Dosing and Administration:

Inside adults 1 tablet 3 times a day with meals.

A tablet should drink 1/2 cup of water.

The course of treatment is at least 3 months. An increase in the duration and conduct of repeated courses of treatment is possible on the recommendation of a doctor.

Side effects:

Possible allergic reactions (redness, skin rash, swelling, itching, urticaria), decreased blood clotting and the possibility of bleeding (with prolonged use), eczema, headache, dizziness, tinnitus, gastrointestinal disorders (nausea, vomiting, abdominal pain , dyspepsia, diarrhea). In the event of any undesirable events, the drug should be discontinued and consult your doctor.

Overdose:

To date, cases of overdose have not been documented.

Interaction:

In clinical trials with EGb 761, both inhibition and induction of cytochrome P450 isoenzymes were detected: In a co-administration EGb 761 with midazolam, the level of the latter changed presumably because of the effect on CYP3A4. Therefore, care must be taken when sharing EGb 761 and drugs metabolized by isoenzyme CYP3A4 and having a low therapeutic index.

Do not take the drug to patients systematically using acetylsalicylic acid (as an antiaggregant drug), anticoagulants (direct and indirect action), and other drugs that reduce blood clotting.

Special instructions:

Before use of the drug requires a doctor's consultation. Improvement of the condition manifests itself 1 month after the start of treatment.

Effect on the ability to drive transp. cf. and fur:

During the period of taking the drug, it is not recommended to perform potentially dangerous the types of activities that require an increased concentration of attention and speed of psychomotor reactions (including the management of vehicles,work with moving mechanisms), since the drug may cause dizziness.

Form release / dosage:

Film coated tablets 40 mg.

Packaging:For 15 tablets in a blister of PVC and aluminum foil. For 2 or 6 blisters together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

Store at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:Without recipe

Registration number:П N011709 / 01

Date of registration:01.11.2011

The owner of the registration certificate:IPSEN PHARMA IPSEN PHARMA France

Manufacturer: & nbsp

BEAUFOUR IPSEN INDUSTRIE France

Information update date: & nbsp13.12.2015

Illustrated instructions

Instructions

Tanacan® (Tanakan®)